{"type":"trials","record":{"id":87179,"source_id":"isrctn","external_id":"ISRCTN81595685","title":"Age-related macular degeneration Meso-zeaxanthin Ocular Supplementation trial (AMOST)","brief_summary":"Age-related macular degeneration (AMD), the late stage of age-related maculopathy (ARM), is the most common cause of blind registration in the western world. It is estimated that AMD affects approximately 1.4 million individuals in United States, 417,000 people in the United Kingdom and 70,000 people in the Republic of Ireland, and this number is likely to increase due to increasing longevity. Although the aetiological mechanisms leading to ARM are uncertain, there is a growing consensus that cumulative short wavelength (blue) light damage and/or oxidative stress play a role in this disease. The central retina, known as the macula, is responsible for central, colour and fine-detail vision. A pigment, composed of the three dietary hydroxycarotenoids, lutein (L) and zeaxanthin (Z), and meso-zeaxanthin (MZ) (MZ is also formed in the retina following conversion from L), accumulates at the macula where it is known as macular pigment (MP). MP is a blue light filter and a powerful antioxidant, and is therefore believed to protect against ARM. In addition, there is good reason to believe why supplementation with L, Z and MZ would enhance a patient’s retinal sensitivity. Several studi…","overall_status":"Completed","phases":["Not Applicable"],"study_type":"Interventional","sponsor":"Howard Foundations Holdings Limited (UK)","enrollment":50,"countries":["Ireland"],"start_date":"2009-03-01","completion_date":"2012-03-01","last_update_date":"2011-11-30","source_url":"https://www.isrctn.com/ISRCTN81595685","editorial_summary":"A registered Not Applicable study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Adult","comparator":null,"attribution":"Source: ISRCTN ISRCTN81595685; retrieved 2026-09-25","interventions":["Lutein (L), zeaxanthin (Z), meso-zeaxanthin (MZ)","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["Measured at baseline, three months, six months and twelve months: 1. Morphological changes in AMD, with respect to base…","Measured at baseline, three months, six months and twelve months: 1. Serum MZ, L and Z concentrations as measured by hi…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Age-related macular degeneration","Group 1: MZ 10 mg; L 10 mg; Z 2 mg (intervention group 1) Group 2: 10 mg L plus an additional contamination of circa 1…","Lutein (L), zeaxanthin (Z), meso-zeaxanthin (MZ)","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":35,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn81595685","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2009-03-01 to 2012-03-01","comparator":null,"confidence":"structured-source","population":"All · Adult","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.593Z","intervention":["Lutein (L), zeaxanthin (Z), meso-zeaxanthin (MZ)","Drug"],"participants":50,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Not Applicable","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Measured at baseline, three months, six months and twelve months: 1. Morphological changes in AMD, with respect to base…","Measured at baseline, three months, six months and twelve months: 1. Serum MZ, L and Z concentrations as measured by hi…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87179","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}